Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 385 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. October 17, 2019 ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ March 8, 2019 New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo... September 13, 2019 EMA Recommends Extension of Therapeutic Indications for Trifluridine/Tipiracil July 7, 2023 Load more HOT NEWS Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... How to Tell If Cancer Information on Social Media Is “Fake... Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers
